A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Paddock Laboratories, Inc.
• Treatments: Moexipril

Criteria

Inclusion Criteria:

• Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion Criteria:

• Positive test results for HIV or Hepatitis B or C

• History of allergy or sensitivity to Moexipril HCl or related drugs